[HTML][HTML] A convenient truth: Cost of medications need not be a barrier to hepatitis B treatment

M Barnhart - Global Health: Science and Practice, 2016 - ghspjournal.org
Drugs that are inexpensive to manufacture and simple to administer greatly expand the
potential to help tens of millions of people who need treatment for chronic hepatitis B virus …

Cost‐effectiveness of treating all hepatitis B–positive individuals in the United States

D Razavi‐Shearer, C Estes… - Journal of Viral …, 2023 - Wiley Online Library
Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related
mortality globally. However, most of the infected individuals in the United States remain …

Extending treatment eligibility for chronic hepatitis B virus infection

AL McNaughton, M Lemoine, C van Rensburg… - Nature Reviews …, 2021 - nature.com
Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to
support enhanced prevention, diagnosis and treatment. On the basis of insights from …

How to improve access to therapy in hepatitis B patients

M Subic, F Zoulim - Liver International, 2018 - Wiley Online Library
Despite the availability of a preventive vaccine and active antiviral treatments that stop
disease progression and reduce the risk of hepatocellular carcinoma, hepatitis B is still a …

Economic analyses to inform and support health policy for chronic hepatitis B treatment

M Toy, DW Hutton, S So - Current Hepatology Reports, 2019 - Springer
Abstract Purpose of Review Summarize insights into the economic impact of global hepatitis
B treatment policies. Recent Findings With the highly effective antiviral treatment, entecavir …

The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023

A Stockdale, B Holt, A Bhadoria, D Ikeda… - …, 2023 - livrepository.liverpool.ac.uk
Background: Globally, less than 10% of 296 million with chronic hepatitis B virus (HBV)
infection had been diagnosed and only 2% treated. Increasing access to HBV care and …

Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment

C Freeland, R Racho, M Kamischke… - Journal of Viral …, 2021 - Wiley Online Library
Those living with chronic hepatitis B virus (HBV) require years, if not decades, of regular
monitoring to prevent liver complications from occurring. An estimated 292 million people …

Examining the hepatitis B care cascade through an equity lens

HN Kim - JAMA Network Open, 2023 - jamanetwork.com
In 2016, the World Health Organization called for the elimination of hepatitis B (HBV) and
hepatitis C as a public health threat by 2030. Since then, more research has been published …

[HTML][HTML] Access to care and optimal treatment of chronic hepatitis B in Asian Americans: an evolving agenda

EB Keeffe - Digestive diseases and sciences, 2011 - Springer
Chronic hepatitis B (CHB) is an important public health problem and a leading cause of liver-
related morbidity and mortality worldwide, particularly in the Asia Pacific region [1]. In the …

Meeting the WHO and US goals to eliminate hepatitis B infection by 2030: opportunities and challenges

BJ McMahon - Clinical liver disease, 2018 - journals.lww.com
Hepatitis B virus (HBV) infection is a significant cause of morbidity and mortality in the world.
1 The results of a study by the Institute for Health Metrics and Evaluation concluded that viral …